

14 Apr 2021 | News

QUOTED. 14 April 2021. Michael Coyle.

by

Medicare carrier Novitas raised its reimbursement rates for continuous cardiac monitoring, but iRhythm has concluded that the rates are still too low and is preparing to discontinue serving its Medicare segment. See what iRhythm CEO Michael Coyle said about it here.

“Unless we are able to establish rates for these codes that allow us to sustainably provide the Zio XT service, we will be forced to stop servicing the Medicare fee-for-service segment under these building codes.” – Michael Coyle, CEO, iRhythm

- Find out more: [Reimbursement Dispute Between Novitas And iRhythm Hits An Impasse](#)

[Click here](#) for a free trial of *Medtech Insight*